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Retransplantation in Alport post-transplant anti-GBM disease.
Background. Post transplant anti-glomerular basement
membrane (GBM) disease affects up to 5% of patients with
Alport’s syndrome. Defects in the COL4A5 gene are respon-
sible for most cases, and a5(IV)NC1 is the usual target for al-
loantibodies. Gene deletions are more commonly associated
with this complication than are point mutations. The disease is
severe in renal allografts and nearly always results in graft loss.
Methods. Three cases of retransplantation in Alport’s syn-
drome are described here in detail. All cases were started on
immunosuppressive therapy early in the course of their disease
and one patient (case 2) received pre-emptive anti–T-cell ther-
apy (Campath IH). Anti-GBM antibodies in these cases were
investigated by standard anti-GBM enzyme-linked immunosor-
bent assay (ELISA), by indirect immunofluorescence, and by
Western blotting using collagenase-digested human GBM and
recombinant type IV collagen NC1 domains made in insect cells.
Results. All cases showed early antibody and complement fix-
ation to human GBM. Target alloantibodies were to a5(IV)NC1
domain predominantly. Cases two and three gave negative re-
sults on standard ELISA for anti-GBM antibodies. Pathologic
examination revealed crescentic glomerulonephritis, which was
rapid in onset in case 1, blunted and less aggressive in case 3,
and case 2 developed segmental necrosis without crescent for-
mation. Neutrophilic infiltrates were an early feature in all 3
cases. All cases are compared with a review of all retransplanted
cases in the literature.
Conclusion. Alport anti-GBM disease is a severe disease in
retransplanted patients. Anti–T-cell therapy seemed to modify
the pathologic findings but did not prevent graft loss. Longer
term plasma exchange and mycophenolate mofetil may atten-
uate the illness, but in these cases did not prevent graft loss.
Western blotting detected alloantibodies to a5(IV) NC1 do-
main and is more sensitive and specific for this disease than
standard ELISAs.
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Approximately 5% of patients with Alport’s syndrome
develop anti-glomerular basement membrane (GBM)
disease in their renal allografts. This does not occur fre-
quently enough to have severe impact on the overall
outcome of transplantation in Alport’s syndrome [1, 2],
but it has a major impact on those patients who are
affected. The disease, once recognized, almost always
destroys the allograft. Retransplantation is rarely suc-
cessful, and therefore these (mostly young) individuals
face many decades of dialysis treatment.
The majority of cases of Alport’s syndrome are asso-
ciated with defects in the COL4A5 gene, which encodes
the a5 chain of type IV collagen. The disease appears to
be more likely to occur in patients with a gene deletion,
rather than a point mutation [1, 3]. It is therefore more
likely to occur in patients with complete absence of the
protein, rather than in those who produce an abnormal
protein. Our previous work [4] has suggested that the
major target of anti-GBM alloantibodies in this setting
is usually the NC1 domain of the type IV collagen chain
implicated in disease causation, and therefore most com-
monly is a5(IV)NC1. These findings were predicted by
previous observations that had suggested that the target
of such alloantibodies was similar to, but distinct from, the
Goodpasture antigen, a3(IV)NC1, which is the target of
spontaneous anti-GBM (Goodpasture’s) disease.
The literature contains 11 cases in which retransplan-
tation has been described, although the details are often
sparse. Here we describe three patients whom we have
studied in some detail. Two cases followed the common
pattern of accelerated disease occurring on retransplan-
tation. One of these showed classic anti-GBM crescen-
tic nephritis, but the other, who had received anti–T-cell
antibodies from day 0, showed no or minimal crescent
formation. The third had less aggressive disease, which
appeared to be partially controlled by therapy. Each case
illustrates different and important points relevant to the
management of this rare disease, and generally more il-
lustrative of crescentic glomerulonephritis.
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METHODS
Western blotting
The target of anti-GBM antibodies was established as
previously described [4]. Briefly, collagenase digests of
human GBM and preparations of recombinant a1, a3,
a5 (IV)NC1 were separated on 12.5% 8 × 10 cm sodium
dodecyl sulfate-polyacrylimide gel electrophoresis (SDS-
PAGE) gels and electroblotted to nitrocellulose mem-
branes (Schleicher & Schuell Bioscience GmbH, Dassel,
Germany) using a wet system, overnight at 30 mA. All
samples were run in nonreducing conditions. Blotted
membranes were blocked with phosphate-buffered saline
(PBS) containing 1% Tween before being incubated with
patient’s or control serum for 1 hour, then washed 3 times
with PBS containing 0.1% Tween 20 (PBS/Tw). Each set
of strips was then incubated with an appropriate alka-
line phosphatase-conjugated polyclonal secondary anti-
body (Sigma Chemical Co., St. Louis, MO, USA) and
washed in the same way. Incubated strips were devel-
oped with nitroblue tetrazolium and 5-bromo-4-chloro-
3-indolyl phosphate [5].
Immunohistochemistry
For indirect immunofluorescence studies of skin, 4 mi-
cron sections were air-dried and fixed in 95% ethanol at
4◦C for 5 minutes, followed by 3 rinses in PBS at room
temperature. The sections were then incubated in 6 mol/L
urea, 0.1 mol/L glycine, pH 3.5, for 1 hour at 4◦C [6]. The
denatured sections were reacted at room temperature
with normal human serum or patient serum, followed by
fluoroscein isothiocyanate (FITC)-conjugated goat anti-
human immunoglobulin G (IgG) (BioRad Laboratories,
Ltd., Hemel Hempstead, UK), and viewed under an epi-
fluorescence microscope with appropriate filters.
Case descriptions
All the patients were males who developed their first
manifestations of Alport syndrome before the age of
10 years.
Case 1. Haematuria and proteinuria were noted at age
6, mild sensorineural deafness at age 8, and lenticonus
later in life. No family history was available and the
nature of the genetic lesion underlying his disease was
not known. At age 33, the patient presented with end-
stage renal failure. One year later cadaveric renal trans-
plantation was performed, with good early function. At
9 months, creatinine had risen from 165 to 210 lmol/L,
and renal biopsy showed crescentic glomerulonephritis.
Despite treatment with pulses of prednisolone the disease
progressed rapidly and graft nephrectomy was performed
shortly afterwards.
Seven years later a second allograft was undertaken,
with a single HLA-A mismatch. There was no immediate
graft function, and biopsies were undertaken on days 3,
6, and 15. The patient was treated from day 7 with pulsed
methylprednisolone and cyclophosphamide, to which im-
munoadsorption against protein A was added on day 9.
On day 22, immunosuppressive treatment was stopped
because the patient developed pneumonia and there had
been no renal recovery. A graft nephrectomy was sub-
sequently performed. The patient remained on mainte-
nance haemodialysis subsequently.
Case 2. Sensorineural deafness and hematuria were
noted in childhood and the patient started hemodialy-
sis at the age of 25. The patient’s maternal uncle died
of renal failure aged 15 years; the patient’s mother and
daughter both have hematuria. An insertion mutation
was found in the COL4A5 coding region, leading to a
premature stop codon that deletes the entire NC1 do-
main from the encoded protein. Indirect immunofluo-
rescence studies confirmed absence of a5(IV)NC1 from
the patient’s epidermal basement membrane. At age 26,
the patient received a renal transplant from his father,
which was removed after 6 months because of repeated
rejection. Glomeruli were reported to be normal in the
nephrectomy specimen (not available for review). A ca-
daver organ was transplanted when the patient was age
32 but failed at 8 weeks in association with crescentic
glomerulonephritis with linear fixation of IgG and C3 to
the GBM. Methylprednisolone was given from day 9 and
OKT3 from day 20. Five years later a third transplant
was undertaken. The donor’s human leukocyte antigen
(HLA) type differed at one A and one B locus. Campath-
IH [7] was given as anti–T-cell therapy in addition to cy-
closporine and prednisolone. There was no immediate
graft function and renal biopsies were performed at days
5, 9, 22, 35, and 51. Intensive plasma exchange and oral cy-
clophosphamide were given from day 9. Subsequent anal-
ysis showed rapid suppression of anti-GBM antibodies,
and peripheral lymphocytes remained suppressed to al-
most undetectable levels (lymphocyte count 0.1 × 109/L
or less) for over six weeks. No useful recovery of renal
function was seen, while histologic changes progressed.
Recovery was complicated by the development of Pneu-
mocystis pneumonia requiring ventilatory support, from
which the patient made a good recovery. Graft nephrec-
tomy was performed on day 97. The patient remained on
maintenance hemodialysis.
Case 3. The patient started hemodialysis at age 18 years,
having developed renal failure and sensorineural deaf-
ness in childhood. Three maternal uncles had died of re-
nal failure, and a large deletion of COL4A5, including
most of the coding region, was been identified. His first
and second renal transplants were described previously
[8]. No evidence of glomerular disease was observed in
the first transplant, but severe anti-GBM disease was seen
at day 17 after the second transplant. A third transplant
was performed when the patient was 26. HLA type was
mismatched at one B locus. There was immediate graft
function, and creatinine fell to 170 lmol/L at day 10, sub-
sequently increasing to 220 by day 20, and 320 by day 30,





















Fig. 1. Enzyme-linked immunosorbent assay (ELISA) for anti-
glomerular basement membrane (GBM) antibodies in case 1. Values
in an ELISA based on a crude collagenase digest of human GBM (CS-
GBM) are compared with those from purified sheep a3(IV)NC1 (a3
monomer) [9].
at which time the patient also developed hematuria with
red cell casts and proteinuria of 8 g/day. At day 45 the
patient was treated with methylprednisolone, cyclophos-
phamide, and intensive plasma exchange (daily for 5 days,
alternate days to day 58, 3 times weekly for one month,
2 to 3 times weekly for 3 months). Two months later
(9 months’ post-transplant) plasma exchange was recom-
menced 3 times weekly, and mycophenolate mofetil 1 g
daily was administered. After 6 weeks this was doubled
and plasma exchange was reduced to twice weekly, con-
tinuing for 3 months. During this time renal function and
proteinuria remained stable but poor, with a serum crea-
tinine of approximately 300 lmol/L. Anti-a5(IV)NC1 an-
tibodies became undetectable. Over the next 18 months
renal function slowly declined without evidence of con-
tinuing disease, and the patient returned to hemodialysis
30 months after transplantation. Graft nephrectomy was
performed two years later because of hematuria.
Anti-GBM antibodies
The nature of anti-GBM antibodies in these pa-
tients was investigated by standard anti-GBM antibody
enzyme-linked immunosorbent assay (ELISA), by indi-
rect immunofluorescence, and by Western blotting us-
ing collagenase digests of human GBM, and recombinant
type IV collagen NC1 domains made in insect cells [4].
Case 1. Although the titers of anti-GBM antibodies in
this patient were high, a discrepancy was noted between
values obtained in the standard anti-GBM assay, for
which the ligand was purified sheep a3(IV)NC1, and in an
assay using crude unpurified collagenase digests of GBM
from human kidney, which contains NC1 domains from
a1-a5 chains (Fig. 1). Early in the clinical course, there
was strong binding to human GBM, but poor binding to
purified sheep a3(IV)NC1. This difference lessened as
the disease progressed, suggesting an increasingly broad
immune response involving a3(IV)NC1 as a secondary
phenomenon. Such discrepancies are not encountered in
Fig. 2. (A) Indirect immunofluorescence using protein A–purified im-
munoglobulin G (IgG) from case 1, sections of normal human kidney
(left, patient; right, normal serum) and (B), denatured sections of hu-
man epidermis (left, patient; right, normal serum). Binding of IgG to
epidermal basement membrane is indicated by the arrow.
patients with spontaneous anti-GBM disease [9]. By indi-
rect immunofluorescence this patient’s sera also showed
strong binding to acid-urea–treated epidermal basement
membrane, a pattern not observed with sera from pa-
tients with spontaneous anti- with spontaneous anti-anti-
GBM (Goodpasture’s) disease (Fig. 2). Western blotting
experiments using collagenase-solubilized human GBM
and recombinant antigens (patient c in Brainwood et al,
1998 [4]) had shown that the predominant target of these
alloantibodies was a5(IV)NC1, with lesser recognition of
a3(IV)NC1 (patient c in Brainwood et al, 1998). Cross-
inhibition studies then showed that this binding was due
to dual specificities, not to cross-reacting epitopes [4].
Cases 2 and 3. These sera contained lower titers of
antibody than case 1, and in both cases standard assays
for anti-GBM antibodies gave negative results. Indirect
immunofluorescence on epidermal basement membrane
was positive but weaker than in case 1. Investigations un-
dertaken as described above again showed that the anti-
bodies were directed toward a5(IV) NC1; cases 2 and 3
were patients b and a, respectively, in the study of Brain-
wood et al [4].
PATHOLOGY
Examples of pathologic findings from each patient are
shown in Figure 3.
Patient 1
Light microscopy of the biopsy taken on day 3 revealed
interstitial infiltrates but no tubulitis. Numerous neu-
trophils were noted in the glomerular capillaries. These
persisted at day 6, but in addition there were numerous
areas of necrosis and occasional cellular crescents. Di-
rect immunofluorescence showed strong linear binding
of IgG and C3 to the GBM. By day 15 all 18 glomeruli
in the biopsy showed necrotizing lesions with fibrin de-
position and crescents. Very extensive basement mem-
brane damage had occurred, only one or two glomeruli
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showing retention of basic structure. There were focal
tubular infiltrates without overt tubulitis.
Patient 2
A biopsy taken 5 days after transplantation showed
normal glomerular appearances. Acute tubular necro-
sis, presumably related to previous cold ischemia,
was present. Direct immunofluorescence examination
showed weak, linear staining for IgG along the GBM.
On day 9 there was a diffuse, marked increase in mesan-
gial matrix and scattered neutrophil polymorphs within
the glomerular capillary lumina. A segmental lesion com-
prising fibrinoid material was present in the mesangium
of one glomerulus. Strong, linear IgG staining along the
GBM was associated with C3 deposition. By day 22 pro-
gression had occurred with marked mesangial matrix
deposition, mild mesangial hypercellularity, numerous
glomerular neutrophils, GBM wrinkling, and segmental
proliferative lesions. A single sclerosed glomerulus and
mild tubular atrophy were present, but there was no ev-
idence of rejection. Similar IgG and C3 deposition was
noted on direct immunofluorescence. At 35 days there
was widespread segmental proliferation, GBM thicken-
ing, and gross expansion of the mesangial matrix. At day
51 there were, in addition, occasional ‘fibrinous’ crescents
and foci of glomerular necrosis and segmental necro-
sis. Arterial changes were apparent and comprised fibri-
noid change within arterioles and subendothelial intimal
change within the walls of larger, intralobular arteries.
By the time of removal of the transplant kidney there was
widespread necrosis and crescent formation with both fib-
rinous and more classic cellular crescent formation within
glomeruli, associated with marked tubular atrophy.
Patient 3
The first biopsy at day 35 showed focal necrotizing
proliferation with marked neutrophil infiltration of the
mesangium of one glomerulus, while the remaining two
glomeruli appeared normal. The second biopsy at day 44
showed cellular crescents with a focal necrotizing lesion in
3 out of 5 glomeruli. There was evidence of acute tubular
necrosis. By direct immunofluorescence, linear staining
for IgG and C3 was seen on the GBM, Bowman’s capsule,
and in distal tubules (Fig. 3). A further biopsy performed
at day 90 showed less acute inflammation but signs of
glomerular scarring, mild focal tubular atrophy, and in-
terstitial edema. By day 180 there was advanced chronic
renal damage with global and focal glomerulosclerosis.
DISCUSSION
The usual pattern of disease described in patients with
Alport’s syndrome who develop anti-GBM disease is of
disease destroying the first allograft after months or years,
the second is destroyed in weeks to months, and third
or subsequent grafts are lost in days to weeks. Cases 1
and 2 described here fit that pattern. Case 3 differed in
that the patient’s first transplant did not seem to pro-
voke anti-GBM disease, and in their third transplant the
disease appeared slower and more treatable. Previous
accounts have come from the 11 cases of retransplan-
tation that have been described in the literature over
16 years (Table 1) and from anecdotal experiences. Of
published cases, 8 have appeared to follow the typical
pattern described above of accelerating disease in subse-
quent allografts. Three patients retained subsequent al-
lografts, but one late loss was attributed to other causes.
No particular measures were taken to prevent disease re-
currence in these three patients, and there are no other
obvious reasons to explain why they remained tolerant of
subsequent allografts, which must have contained the
same alloantigens as those to which they had previ-
ously developed strong immune responses and disease.
Immunosuppression in all three cases was comparable
to that given to other patients. Treatments adminis-
tered in attempt to arrest or reverse this complication
have usually at first been identical to therapy for acute
rejection—which is the usual initial diagnosis. There are,
therefore, several recorded instances of lack of success
with high-dose corticosteroids (most reported cases) and
anti-lymphocyte antibodies (e.g., 4 of the patients in
Table 1). Plasma exchange seems a rational treatment, as
it is likely that by analogy with spontaneous anti-GBM
disease, the disease is in large part antibody-mediated.
The unsuccessful use of plasma exchange is recorded in
several cases (e.g., 4 instances in Table 1). However, in
almost all of the reported cases, even in recurrences of
disease in subsequent transplants, the correct diagnosis
has often been realized at a relatively late stage, and the
apparent failures of treatment may not accurately reflect
the potential value of these therapies if delivered earlier
in the disease process.
One reason for late diagnosis is sometimes the fail-
ure of standard assays for anti-GBM antibodies (opti-
mized for anti-a3(IV)NC1 antibodies) to identify the
anti-a5(IV) antibodies that seem most commonly to typ-
ify this disease. Western blotting is not readily available
in most centers (although it is simple enough), and we
have found that indirect immunofluorescence on skin (as
shown in Fig. 2) is insensitive and only works well with
high-titer antibodies. Direct immunofluorescence studies
of renal biopsies are the most sensitive and rapid way of
identifying anti-GBM antibodies, though linear binding
of IgG may be commonly seen without accompanying
anti-GBM disease [20].
In all of our patients the correct diagnosis was appre-
ciated very quickly, and, in one patient (case 2), antici-
pated. In this case we elected (with the agreement of the
patient) for pre-emptive treatment with an anti–T-cell
therapy, choosing a humanized agent so that recur-
rent treatment would be possible. We reasoned that the
antibody response was likely to be T-cell–dependent,
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Fig. 3. Pathologic studies of cases 1–3. De-
scriptions are given in the text. All are hema-
toxylin and eosin sections with the exception
of Case 2, day 22 (neutrophil elastase), Case 2,
day 51 (MSB stain). Case 3, second and third
images from day 44 (direct immunofluores-
cence for IgG).
and that crescentic glomerulonephritis, the usual pattern
in anti-GBM disease, has been found in animals to be
T-cell–dependent [21]. In this patient crescentic glomeru-
lonephritis did indeed appear to be suppressed—but
glomerular damage was not, and graft function was lost
rapidly without the appearance of cellular crescents until
a late stage.
In the three patients described here, antibody and
complement fixation to the GBM appeared early, and
possibly as the first manifestation of glomerular pathol-
ogy. Very prominent neutrophil infiltration was an early
feature, and it persisted over a long period. In case 3,
numerous neutrophils were involved in substantial in-
terstitial inflammation and tubulitis. Other reports have
made similar observations (e.g., Diaz et al [17]). As
a5(IV) collagen is known to be present in distal
tubules/collecting ducts (as shown by immunofluores-
cence in Figs. 2 and 3), an inflammatory response in-
volving some tubules could be expected. As tubulitis is
also a part of cellular rejection, it may be difficult to dif-
ferentiate the two, although neutrophils are not usually
prominent in acute rejection. Could acute rejection trig-
ger anti-GBM disease as a secondary response, once
tubules have been damaged and alloantigens released
from tubular basement membranes? Some case histories
are suggestive of this.
Do these experiences suggest management strategies
for other patients? It is our clear impression that plasma
exchange is beneficial, at least in retarding the tempo of
the disease. This provides indirect support for antibody-
mediated damage, which may be added to by our own,
and by previous evidence that anti–T-cell therapies are
inadequate. However, there is also clear evidence that an-
tibody formation can occur in the absence of disease [1,
20, 22–24], although there could be quantitative or qual-
itative differences in the anti-GBM response in patients
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Table 1. Previously reported examples of retransplantation in Alport anti-GBM disease
Months Time Anti-
to graft between GBM
Report Graft failure grafts disease Mutation Treatment Outcome Comments
Rassoul et al, 1990 1st 4 + NK PE CNGL
2nd – 3 years + Delayed onset disease
(18 months), graft
functioning at 2 years
Milliner et al, 1982 1st 14 + NK CNGL
2nd – 8 months + Disease at 7 months,
spontaneous
improvement
Milliner et al, 1982 1st 43 + NK CNGL
2nd – Not stated (+) Graft functioning at
>4 years
Goldman et al, 1990 1st 7 + NK ST CNGL
2nd <1 1 year + ALG, ST “immediate”
recurrence (CNGL)
Shah et al, 1988, 1st 5 + COL4A5 deletion ATG Patient MC,
Kashtan, 1990, 2nd <2 7 years + 111–1,
Ding, 1994 FNS-2, e
Shah et al, 1988, 1st 18 + COL4A5 deletion ST, PE cycph CNGL Patient JM
Kashtan, 1990 2nd 2 weeks 10 months –? ST, PE Acute rejection,
Antibody but no
nephritis
Hudson, 1992 1st 15 + NK CNGL
2nd <1 6 months + PE, ST, cycph CNGL
Vangelista, 1990 1st 4 + NK NK CNGL
2nd 4 months + CNGL
Diaz, 1994 1st 19 + NK Rejection/
2nd ?1 1 year + ALG pyelonephritis
CNGL
Kashtan, 1989 1st 1 + COL4A5 deletion PE, cytotoxics CNGL Patient JE,
Ding, 1994 2nd 3 3 years + PE, cytotoxics CNGL FNS-1, h
This report, Case 1 1st 8 + NK CNGL Patient c
[Brainwood, 1998] 2nd 2 weeks 7 years + PE, ST, cycph CNGL
This report, Case 2 1st 6 – COL4A5 premature Chronic rejection Patient b
[Brainwood, 1998] 2nd 2 4 years + stop codon
3rd 1 5 years + ST, OKT3, PE, CNGL
cycph, ST, PE
This report, Case 3 1st 24 ? COL4A5 deletion Chronic rejection Patient a
[Oliver, 1991] 2nd 11 days 1 year + ST, PE cycph, CNGL
[Brainwood, 1998] 3rd 30 4 years + PE, MMF Graft lost at 3 years
Soler Pujol, 1999 1st 6 – NK
2nd 11 9 years + PE,ST CNGL/rejection
Abbreviations are: ALG, anti-lymphocyte globulin; ATG, anti-thymocyte globulin; cycph, cyclophosphamide; CNGL, crescentic nephritis, graft lost; MMF, mycophe-
nolate mofetil; NK, not known; PE, plasma exchange; ST, high-dose corticosteroids.
who get disease versus those who do not. T-lymphocytes
certainly contribute to the pathogenesis of the disease,
as antibody responses are likely to be T-cell–dependent,
crescentic glomerulonephritis is T-cell–dependent [21],
and in case 2, the nature of the disease (but not the out-
come) seemed to be influenced by eradication of circu-
lating T-lymphocytes.
Our beliefs about management of this disease are that
in order to be effective, maximal therapies should be in-
stituted as soon as there is clear evidence of glomeru-
lar disease. Antibody production or binding alone is not
evidence of disease. Therapy to remove antibodies is in-
dicated. Anti-complement or anti-neutrophil therapies
may also be effective. Mycophenolate mofetil could be
a useful drug in these circumstances, and of course, this
therapy may be used as part of pre-emptive immunosup-
pression. Antibodies to T-lymphocytes or to activation
markers or adhesion molecules may be useful, but it is
difficult and expensive to maintain levels of therapeu-
tic antibodies in a disease that is also treated by plasma
exchange.
Finally, it is possible that efforts to prevent rejection
from occurring may also be effective in reducing the in-
cidence of sensitization to these alloantigens. They are
probably normally turned over at an extremely low rate
[25], and they may therefore normally be presented to
the immune system only at very low levels. This could
reduce the need for active maintenance of peripheral tol-
erance mechanisms, but place individuals at greater risk
of sensitization if the rate of antigen presentation was
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increased, for instance, by acute inflammation caused by
allograft rejection.
The observation that gene deletions are more likely to
be associated with this disease may be informative. Mu-
tations that generate an abnormal protein are apparently
associated with a lesser rate of anti-GBM disease, even if
the protein fails to be incorporated into GBM [26]. Jais
et al noted that the 3 of their 80 transplanted patients with
COL4A5 mutations who developed anti-GBM disease
all had large gene deletions, whereas others with lesser
mutations, including those predicting trunctations of the
molecule so that it lacked the (apparently immunogenic)
NC1 domain, appeared to be protected from the com-
plication [26] (however, this was not the case for patient
2 in this report). The unincorporated protein is presum-
ably degraded, perhaps allowing some to reach antigen-
presenting cells and be available for tolerizing mecha-
nisms. This cannot at present be fully explained, though
aberrant transcription may conceivably generate small
amounts of correct protein in some individuals.
CONCLUSION
In the future, therefore, patients with large deletions
may be ideal candidates for deliberate induction of spe-
cific immune tolerance to the tissue-specific type IV
collagen chains. Those known to be at increased risk of
developing the disease because of an underlying gene
deletion could be treated pre-emptively, probably using
only the three GBM-specific type IV collagen NC1 do-
mains. However, the risk of inducing sensitization rather
than tolerance would have to be extremely small.
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